Human glandular kallikrein enhancer, vectors comprising the enhancer and methods of use thereof

• US 6,916,918 B2
• Filed: 06/05/2001
• Issued: 07/12/2005
• Est. Priority Date: 08/04/1997
• Status: Expired due to Fees

• Current Assignee: Cell Genesys Incorporated (ANI Pharmaceuticals, Inc.)
• Original Assignee: Cell Genesys Incorporated (ANI Pharmaceuticals, Inc.)
• Inventors: Yu, De Chao, Henderson, Daniel R., Schuur, Eric R.
• Primary Examiner(s): Nguyen, Dave T.
• Assistant Examiner(s): SCHNIZER, RICHARD A
• Application Number:
  US09/875,228
• Publication Number:
  US 20020136707A1
• Time in Patent Office: 1,498 Days
• Field of Search: 536/24.1, 435/320.1, 424/93.2, 424/233.1
• US Class Current: 536/24.1
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: C12N 15/86 Viral vectors
• CPC Class Codes: C12N 2710/10322 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
• CPC Class Codes: C12N 2710/10343 viral genome or elements thereof as genetic vector
• CPC Class Codes: C12N 2830/002 inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
• CPC Class Codes: C12N 2830/008 cell type or tissue specific enhancer/promoter combination

Abstract

Enhancers which preferentially increase the transcription of cis-linked coding sequences in prostate cells are provided. Methods of using DNA constructs comprising the enhancers to control transcription of heterologous polynucleotides are also provided. Delivery vehicles comprising the enhancers and methods of using the vehicles are also provided. Adenovirus vectors in which one or more genes are under transcriptional control of the enhancers of the invention are also provided. Further provided are methods of using the adenovirus vectors of the invention to confer selective cytotoxicity in mammalian cells.

Claims

1. An isolated polynucleotide comprising nucleotides about 8021 to about 8371 of SEQ ID NO:

1, or a fragment thereof of comprising bases 8192-8206 of SEQ ID NO;

1, wherein said polynucleotide or said fragment thereof has prostate-specific enhancer activity.

2. An isolated polynucleotide comprising nucleotides about 8021 to about 8371 of SEQ ID NO:

1, wherein said polynucleotide has prostate-specific enhancer activity.

3. An isolated polynucleotide according to claim 2, wherein the polynucleotide comprises nucleotides about 7200 to about 8371 of SEQ ID NO:

1, wherein said polynucleotide has enhancer activity.

4. An isolated polynucleotide according to claim 2, wherein the polynucleotide comprises nucleotides about 6859 to about 8627 of SEQ ID NO:

1, wherein said polynucleotide has enhancer activity.

5. An isolated polynucleotide according to claim 2, wherein the polynucleotide comprises nucleotides about 5976 to about 9620 of SEQ ID NO:

1, wherein said polynucleotide has enhancer activity.

6. An isolated polynucleotide according to claim 2, wherein the polynucleotide comprises nucleotides about 1 to about 9765 of SEQ ID NO:

1, wherein said polynucleotide has enhancer activity.

7. An adenovirus vector for selective cytolysis of a prostate target cell comprising an adenovirus gene essential for replication under transcriptional control of a human glandular kallikrein transcription regulatory element (hKLK2-TRE), wherein said hKLK2-TRE comprises a promoter and nucleotides about 8021 to about 8371 of SEQ ID NO:

1.

8. The adenovirus vector of claim 7, wherein said adenovirus gene essential for adenoviral replication is selected from the group consisting of E1A, E1B, E2 and E4.

9. The adenovirus vector according to claim 7 wherein said hKLK2-TRE comprises nucleotides about 7200 to about 8371 of SEQ ID NO:

1.

10. The adenovirus vector according to claim 9, wherein said adenovirus gene essential for adenoviral replication is selected from the group consisting of E1A, E1B, E2 and E4.

11. The adenovirus vector according to claim 7 wherein said hKLK2-TRE comprises nucleotides about 6859 to about 8627 of SEQ ID NO:

1.

12. The adenovirus vector according to claim 11, wherein said adenovirus gene essential for adenoviral replication is selected from the group consisting of E1A, E1B, E2 and E4.

13. The adenovirus vector according to claim 7 wherein said hKLK2-TRE comprises nucleotides about 5976 to about 9620 of SEQ ID NO:

1.

14. The adenovirus vector according to claim 7 wherein said hKLK2-TRE comprises nucleotides about 1 to about 9765 of SEQ ID NO:

1.